About Us
About Noxopharm
CEO's Message
Management Team
Board of Directors
Scientific Advisors
Our Network
Pharmorage
ESG Commitment
Technology
Technology Platforms
Chroma™
Sofra™
mRNA Vaccines
Autoimmune Disease
Clinical Trials
Publications
Investor Centre
Share Price
Presentations & Interviews
Annual Reports
Financial Reports
ASX Announcements
Corporate Governance
Investor Fact Sheet
Share Registry Information
Contact Us
Contact Us
Partnering
Working at Noxopharm
ASX Announcements Email Alerts
Investor Centre
Investor Centre
>
ASX Announcements
Share Price
Presentations & Interviews
Annual Reports
Financial Reports
ASX Announcements
Corporate Governance
Investor Fact Sheet
Share Registry Information
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
Older
31 May 2021
Appendix 3G
31 May 2021
Noxopharm Extraordinary General Meeting Results
31 May 2021
New Independent Trial Data Supports Potential of Veyonda
13 May 2021
Noxopharm to Present to Share Cafe Hidden Gems Webinar
12 May 2021
NOXCOVID Trial Achieves Full Enrolment
7 May 2021
Cleansing Notice
7 May 2021
Appendix 2A
7 May 2021
Veyonda FDA Approved Trial to Commence
4 May 2021
Securities Trading Policy
30 Apr 2021
Cleansing Notice
Previous
1
2
3
4
5
6
7
8
9
10
11
Next
